Biomolecules · Nov 17, 2026

Emerging Therapeutic Strategies Targeting Muscle Wasting in Parkinson’s Disease: From Sarcopenia to Cachexia-like Syndrome

By Manole E, Gaina G, Dragnea EM et al.

Clinically relevant muscle wasting affects a substantial proportion of patients with Parkinson’s disease (PD), although its prevalence varies according to the diagnostic criteria applied. This condition accelerates disease progression, reduces quality of life, and is a poor prognostic indicator associated with increased disability and mortality. Despite its clinical relevance, the molecular mechanisms underlying muscle wasting remain underinvestigated and poorly understood, constituting an unmet clinical need. Currently, there is insufficient evidence to definitively establish PD-associated muscle wasting as true cachexia, a syndrome characterized by systemic inflammation and metabolic dysregulation. Moreover, distinguishing the contribution of age-related sarcopenia from PD-specific pathological mechanisms remains challenging. A deeper understanding of the pathways and molecular signals involved in PD-associated muscle wasting may lead to therapeutic strategies to improve patient outcomes. Given the multifactorial nature of PD muscle wasting—e.g., motor neuron degeneration, aging, oxidative stress, inflammation, protein degradation, mitochondrial dysfunction—our aim is to provide a comprehensive overview of the current data on the cellular, molecular, and systemic mechanisms involved in this process. We also identify emerging therapeutic targets that may help prevent, attenuate, or reverse muscle atrophy in PD. Understanding muscle–brain crosstalk may redefine PD as a systemic rather than neurodegenerative disorder.

doi.org/10.3390/biom16111669Open accessMechanisms

AgingResearch.News